Original Research
Accepted on 04 Jun 2025
The changes of metabolites in AP patients
in Gastrointestinal and Hepatic Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1614713
Type at least 3 characters
1,199 articles
Original Research
Published on 04 Jun 2025
Real-world data of Azvudine-induced hepatotoxicity among hospitalized COVID-19 patients in China: a retrospective case-control study
in Gastrointestinal and Hepatic Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1558054
- 951 views
Editorial
Published on 04 Jun 2025
Editorial: Microbiome: the modulator of human health
in Gastrointestinal and Hepatic Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1625412
- 1,026 views
Original Research
Published on 03 Jun 2025
Role of gut microbiota in bempedoic acid against hyperlipidemia: a new candidate target for bempedoic acid on the therapeutic regulation
in Gastrointestinal and Hepatic Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1584273
- 1,026 views
Original Research
Published on 02 Jun 2025
Effects of semaglutide on metabolism and gut microbiota in high-fat diet-induced obese mice
in Gastrointestinal and Hepatic Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1562896
- 645 views
Study Protocol
Published on 30 May 2025
Efficacy and safety of local glucocorticoids for the treatment of acute radiation-induced intestinal injury: protocol of a multicenter randomized controlled trial
in Gastrointestinal and Hepatic Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1529977
- 595 views
Brief Research Report
Published on 30 May 2025
Translational studies on pancreatic cancer and gastric cancer: a methodology in PhD thesis
in Gastrointestinal and Hepatic Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1604017
- 565 views
Systematic Review
Published on 30 May 2025
A systematic review and meta-analysis of efruxifermin’s efficacy in improving liver fibrosis in patients with NASH/MASH
in Gastrointestinal and Hepatic Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1594091
- 779 views
Systematic Review
Published on 27 May 2025
Novel insights from meta-analysis: the efficacy of ginsenosides in non-alcoholic fatty liver disease
in Gastrointestinal and Hepatic Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1564852
- 879 views
Systematic Review
Published on 27 May 2025
Efficacy of interventions with live combined Bacillus subtilis and Enterococcus faecium enteric-coated capsules in metabolic associated fatty liver disease patients: a meta-analysis of randomized controlled trials
in Gastrointestinal and Hepatic Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1610426
- 764 views
Review
Published on 23 May 2025
A potential herbal component for the future treatment of fatty liver disease: Geniposide from gardenia
in Gastrointestinal and Hepatic Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1610676
- 863 views
Review
Published on 22 May 2025
Pharmacological potential of endocannabinoid and endocannabinoid-like compounds in protecting intestinal structure and metabolism under high-fat conditions
in Gastrointestinal and Hepatic Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1567543
- 1,151 views
Original Research
Published on 22 May 2025
Dynamic relationship between gut microbiota and post-necrotizing pancreatitis: insights from a multi-stage 16S rRNA sequencing study
in Gastrointestinal and Hepatic Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1577558
- 722 views
Review
Published on 21 May 2025
Vitamin B5 and vitamin U review: justification of combined use for the treatment of mucosa-associated gastrointestinal pathologies
in Gastrointestinal and Hepatic Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1587627
- 1,540 views
Review
Published on 19 May 2025
Insights into the gut-liver axis: mechanisms and emerging therapies in hepatocellular carcinoma
in Gastrointestinal and Hepatic Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1595853
- 1,173 views
Original Research
Published on 16 May 2025
2-Dodecyl-6-methoxycyclohexa-2,5-dien-1,4-dione alleviates liver fibrosis and improves intestinal flora and bile acid metabolism
in Gastrointestinal and Hepatic Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1581138
- 827 views